Drug
Nbi 921352
Nbi 921352: highest development phase Phase 2, developed by Neurocrine Biosciences. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-921352 NCT05493293 | Phase 2 | Focal Onset Seizure |
| NBI-921352 NCT04873869 | Phase 2 | SCN8A Developmental and Epileptic Encephalopathy Syndrome |
| NBI-921352 NCT05226780 | Phase 2 | SCN8A Developmental and Epileptic Encephalopathy Syndrome |
Latest
No recent events.
Follow Nbi 921352 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.